Akebia Therapeutics, Inc. (FRA:AX9)
Germany · Delayed Price · Currency is EUR | Market Cap | 214.20M -69.2% |
| Revenue (ttm) | 201.56M +25.7% |
| Net Income | -17.79M |
| EPS | -0.07 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.7718 |
| Previous Close | 0.7392 |
| Day's Range | 0.7718 - 0.7718 |
| 52-Week Range | 0.7392 - 3.3700 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia... [Read more]
Financial Performance
In 2025, Akebia Therapeutics's revenue was $236.20 million, an increase of 47.46% compared to the previous year's $160.18 million. Losses were -$5.35 million, -92.30% less than in 2024.
Financial numbers in USD Financial StatementsNews
Akebia announces new Vafseo patent
Akebia (AKBA) announced that a new patent has been granted and listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, and it has been notified of…
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, to...
Akebia Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Vafseo is driving strong growth in both prescribers and patients, with DaVita's broader adoption expected to accelerate in the second half of the year. The pipeline features praliciguat (phase II in FSGS), AKB-097 (basket trial in rare renal diseases), and AKB-9090 (phase I in AKI), with key data readouts and expanded access anticipated through 2027.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, tod...
Akebia Therapeutics Earnings Call Transcript: Q1 2026
Vafseo net product revenue grew 32% year-over-year in Q1 2026, offsetting declines in AURYXIA due to generic competition. Patient and prescriber adoption of Vafseo accelerated, with strong adherence rates and expanding observed dosing protocols, supporting future growth.
Akebia Therapeutics Earnings release: Q1 2026
Akebia Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Akebia Therapeutics Quarterly report: Q1 2026
Akebia Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million ; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared ...
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, tod...
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT CAMBRIDGE, Mass.
Akebia Therapeutics Proxy statement: Proxy filing
Akebia Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Akebia Therapeutics Proxy statement: Proxy filing
Akebia Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Akebia Therapeutics Proxy statement: Proxy filing
Akebia Therapeutics filed a proxy statement on April 15, 2026, providing details for shareholder voting and corporate governance matters.
Akebia doses first participants in AKB-9090 trial
Akebia (AKBA) Therapeutics announced the first participants have been dosed in a Phase 1 clinical trial of AKB-9090, an internally developed hypoxia-inducible factor-prolyl hydroxylase inhibitor being...
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics Transcript: R&D Day 2026
The company is advancing a differentiated pipeline in kidney disease, with praliciguat, AKB-097, and AKB-9090 progressing through key clinical milestones. Vafseo is driving revenue growth, supporting R&D investments, and multiple catalysts are expected in the next year.
Akebia Therapeutics Slides: FY 2026
Akebia Therapeutics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on April 2, 2026.
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The company is focused on making Vafseo the standard of care for dialysis-related anemia, supported by strong clinical and economic data, and is expanding its kidney disease pipeline with praliciguat and AKB-097. Post-TDAPA, pricing will align with ESA benchmarks, targeting a $1B market.
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics Slides: Corporate presentation
Akebia Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on February 27, 2026.
Akebia Therapeutics Earnings Call Transcript: Q4 2025
Net product revenues grew nearly 50% year-over-year to $236.2 million in 2025, driven by Vafseo's launch and Auryxia sales, while net loss narrowed significantly. Vafseo adoption is expanding, with improved adherence and broader access, and the pipeline is advancing with multiple clinical milestones ahead.